Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2002-08-23
2009-02-10
Kim, Jennifer M (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
active
07488723
ABSTRACT:
The invention provides pharmaceutical compositions containing non-feminizing estrogen and methods of using these compositions to prevent or ameliorate retinal vascular diseases.
REFERENCES:
patent: 5504074 (1996-04-01), D'Amato et al.
patent: 5521168 (1996-05-01), Clark
patent: 5843934 (1998-12-01), Simpkins
patent: 5859001 (1999-01-01), Simpkins et al.
patent: 5877169 (1999-03-01), Simpkins
patent: 6001368 (1999-12-01), Jenks
patent: 6197833 (2001-03-01), Simpkins et al.
patent: 2002/0082433 (2002-06-01), Agoston et al.
Green et al. “Nuclear estrogen receptor-independent neuroprotection by estratrienes: A novel interaction with glutathione” Neuroscience vol. 84, No. 1, pp. 7-10, 1998.
Harris-Yitzhak et al. “Estrogen-replacement therapy: Effects on retrobulbar hemodynamics” American Journal of Ophthamology (2000), 129 (5), pp. 623-628.
Alkayed et al., “Neuroprotective effects of female gonadal steroids in reproductively senescent female rats”, Stroke, vol. 31, pp. 161-168 (2000).
Allred et al., “Soy diets containing varying amount of genistein stimulate growth of estrogen-dependent (MCF-7) tumors in a dose-dependent manner”, Cancer Res, vol. 61, pp. 5045-5050 (2001).
Chen et al., “The effects of 17beta-estradiol on ischemia-induced neuronal damage in the gerbil hippocampus”, Neuroscience, vol. 87, pp. 817-822 (1998).
Controneo and Lamartiniere, Pharmacologic, but not dietary, genistein supports endometriosis in a rat model, Toxicol Sci, vol. 61, pp. 68-75 (2001).
Culmsee et al., “Neuroprotection by estrogens in a mouse model of focal cerebral ischemia and in cultured neurons: evidence for a receptor-independent antioxidative mechanism”, J Cereb Blood Flow Metab, vol. 19, pp. 1263-1269 (1999).
Dubal et al., “Estradiol protects against ischemic injury”, J Cereb Blood Flow Metab, vol. 18, pp. 1253-1258 (1998).
Green and Simpkins, “Neuroprotective effects of estrogens: Potential mechanisms of action”, Int J Dev Neurosci, vol. 18, pp. 347-358 (2000).
Harris-Yitzhak M. et al., “Estrogen-replacement therapy: Effects on retrobulbar hemodynamics”, Am J Ophthalmol, vol. 129, pp. 623-628 (2000).
Hawk et al., “Testosterone increases and estradiol decreases middle cerebral artery occlusion lesion size in male rats”, Brain Res, vol. 796, pp. 296-298 (1998).
Hum and Macrae, “Estrogen as a neuroprotectant in stroke”, J Cereb Blood Flow Metab, vol. 20, pp. 631-652 (2000).
Kondo et al., “Estrogen alleviates cognitive dysfunction following transient brain ischemia in ovariectomized gerbils”, Neurosci Lett, vol. 238, pp. 45-48 (1997).
Maggiolini et al., “Estrogen receptor alpha mediates the proliferative but not the cytotoxic dose-dependent effects of two major phytoestrogens on human breast cancer cells”, Mol Pharmacol, vol. 60, pp. 595-602 (2001).
Nonaka et al., “Administration of 17 beta-estradiol attenuates retinal ischemia-reperfusion injury in rats”, Invest Ophthalmol Vis Sci vol. 41, pp. 2689-2696 (2000).
Pelligrino et al., “Cerebral vasodialting capacity during forebrain ischemia: effects of chronic estrogen depletion and repletion and the role of neuronal nitric oxide synthase”, Neuroreport, vol. 9, pp. 3285-3291 (1998).
Rusa et al., “17 beta-estradiol reduces stroke injury in estrogen-deficient female animals”, Stroke, vol. 30, pp. 1665-1670 (1999).
Shi et al., “Effects of 17 beta -estradiol on glucose transporter 1 expression and endothelial cell survival following focal ischemia in the rats”, Exp Brain Res, vol. 117, pp. 200-206 (1997).
Simpkins et al., “Estrogens may reduce mortality and ischemic damage caused by middle cerebral artery occlusion in the female rat”, J Neurosurg, vol. 87, pp. 724-730 (1997).
Toung et al., “Estrogen-mediated neuroprotection after experimental stroke in male rats”, Stroke, vol. 29, pp. 1666-1670 (1998).
Wang et al., “Estrogen provides neuroprotection in transient forebrain ischemia through perfusion-independent mechanisms in rats”, Stroke, vol. 30, pp. 630-637 (1999).
Yannuzzi et al., “Risk factors for central retinal vein occlusion”, Arch Ophthalmol, vol. 114, pp. 545-554 (1996).
Zhang et al., “Effects of gender and estradiol treatment on focal brain ischemia”, Brain Res, vol. 784, pp. 321-324 (1998).
Alcon Inc.
Kim Jennifer M
Schultz Teresa J.
LandOfFree
Use of non-feminizing estrogens as treatment for retinal... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of non-feminizing estrogens as treatment for retinal..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of non-feminizing estrogens as treatment for retinal... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4104578